Details for Patent: 8,415,345
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Which drugs does patent 8,415,345 protect, and when does it expire?
Patent 8,415,345 protects TAFINLAR and is included in one NDA.
This patent has thirty-nine patent family members in thirty-four countries.
Summary for Patent: 8,415,345
| Title: | Benzene sulfonamide thiazole and oxazole compounds |
| Abstract: | The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. |
| Inventor(s): | Adjabeng; George (Durham, NC), Adams; Jerry Leroy (Collegeville, PA), Dickerson; Scott Howard (Durham, NC), Hornberger; Keith (Mount Sinai, NY), Johnson; Neil W. (Collegeville, PA), Kuntz; Kevin (Durham, NC), Petrov; Kimberly (Durham, NC), Ralph; Jeffrey M. (Collegeville, PA), Rheault; Tara Renae (Durham, NC), Schaaf; Gregory (Durham, NC), Stellwagen; John (Durham, NC), Tian; Xinrong (Collegeville, PA), Uehling; David E. (Durham, NC), Waterson; Alex G. (Durham, NC), Wilson; Brian (Durham, NC) |
| Assignee: | Glaxo SmithKline LLC (Philadelphia, PA) |
| Application Number: | 12/991,004 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Process; |
Drugs Protected by US Patent 8,415,345
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST. | ⤷ Sign Up | ||
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST | ⤷ Sign Up | ||
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF MELANOMA | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,415,345
| PCT Information | |||
| PCT Filed | May 04, 2009 | PCT Application Number: | PCT/US2009/042682 |
| PCT Publication Date: | November 12, 2009 | PCT Publication Number: | WO2009/137391 |
International Family Members for US Patent 8,415,345
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071617 | ⤷ Sign Up | |||
| Australia | 2009244491 | ⤷ Sign Up | |||
| Brazil | PI0912541 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
